157 related articles for article (PubMed ID: 3123446)
1. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
[TBL] [Abstract][Full Text] [Related]
2. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
Huhtaniemi I; Nikula H; Rannikko S
J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
[TBL] [Abstract][Full Text] [Related]
3. Steroid sulfates in testis tissue of prostatic cancer patients treated for six months with the gonadotropin releasing hormone agonist buserelin.
Huhtaniemi I; Rannikko S; Orava M; Vihko R
J Steroid Biochem; 1989 Jun; 32(6):811-3. PubMed ID: 2502686
[TBL] [Abstract][Full Text] [Related]
4. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
7. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Huhtaniemi I; Nikula H; Rannikko S; Clayton R
J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
[TBL] [Abstract][Full Text] [Related]
8. Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men.
Schaison G; Brailly S; Vuagnat P; Bouchard P; Milgrom E
J Clin Endocrinol Metab; 1984 May; 58(5):885-8. PubMed ID: 6423662
[TBL] [Abstract][Full Text] [Related]
9. Lack of a direct effect of gonadotropin hormone-releasing hormone agonist on human testicular steroidogenesis.
Rajfer J; Sikka SC; Swerdloff RS
J Clin Endocrinol Metab; 1987 Jan; 64(1):62-7. PubMed ID: 3023429
[TBL] [Abstract][Full Text] [Related]
10. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
[TBL] [Abstract][Full Text] [Related]
11. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.
Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A
J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone and its agonist inhibit testicular luteinizing hormone receptor and steroidogenesis in immature and adult hypophysectomized rats.
Bambino TH; Schreiber JR; Hsueh AJ
Endocrinology; 1980 Oct; 107(4):908-17. PubMed ID: 6250797
[TBL] [Abstract][Full Text] [Related]
13. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Huhtaniemi I; Parvinen M; Venho P; Rannikko S
Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonist analog-induced steroidogenic lesion in the neonatal rat testis: evidence for direct gonadal action.
Huhtaniemi IT; Clayton RN; Catt KJ
Endocrinology; 1984 Jul; 115(1):233-8. PubMed ID: 6329649
[TBL] [Abstract][Full Text] [Related]
16. The effects of a gonadotropin-releasing hormone agonist on testicular histology.
Waxman J; Lowe D; Whitfield HN; Hendry BF; Besser GM
Fertil Steril; 1987 Dec; 48(6):1067-9. PubMed ID: 3119372
[TBL] [Abstract][Full Text] [Related]
17. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
Huhtaniemi IT; Dahl KD; Rannikko S; Hsueh AJ
J Clin Endocrinol Metab; 1988 Feb; 66(2):308-13. PubMed ID: 3123510
[TBL] [Abstract][Full Text] [Related]
18. Regulation of infant and developing rat testicular gonadotropin and prolactin receptors and steroidogenesis by treatments with human chorionic gonadotropin, gonadotropin-releasing hormone analogs, bromocriptine, prolactin, and estrogen.
Huhtaniemi IT; Warren DW; Catt KJ
Biol Reprod; 1985 May; 32(4):721-32. PubMed ID: 2988657
[TBL] [Abstract][Full Text] [Related]
19. Induction and maintenance of gonadotropin and lactogen receptors in hypoprolactinemic rats.
Huhtaniemi IT; Catt KJ
Endocrinology; 1981 Aug; 109(2):483-90. PubMed ID: 6265191
[TBL] [Abstract][Full Text] [Related]
20. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
